NASDAQ: PMNPromis Neurosciences Inc Stock Ownership - Who owns Promis Neurosciences?
Insider buying vs selling
Have Promis Neurosciences Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Neil Cashman | Chief Scientific Officer | 2025-02-10 | 15,000 | $0.97 | $14.60kBuy |
| Madge K. Shafmaster | Director | 2024-09-24 | 70,000 | $1.30 | $91.00kBuy |
| Madge K. Shafmaster | Director | 2024-09-23 | 70,000 | $1.28 | $89.67kBuy |
| Madge K. Shafmaster | Director | 2024-09-20 | 60,000 | $1.25 | $75.06kBuy |
| Michael S. Gordon | 10% Owner | 2024-09-17 | 16,292 | $1.40 | $22.81kBuy |
| Michael S. Gordon | 10% Owner | 2024-09-16 | 76,931 | $1.22 | $94.09kBuy |
| Patrick D. Kirwin | Director | 2024-08-14 | 10,000 | $1.25 | $12.49kBuy |
PMN insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when PMN insiders and whales buy or sell their stock.
PMN Shareholders
What type of owners hold Promis Neurosciences Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Jeremy M. Sclar | 13.17% | 4,305,600 | $2.02M | Insider |
| Great Point Partners LLC | 8.09% | 2,645,128 | $1.24M | Institution |
| Armistice Capital LLC | 7.14% | 2,334,826 | $1.10M | Institution |
| Michael S. Gordon | 6.50% | 2,123,962 | $998.26k | Insider |
| 19 Promis Title | 6.35% | 2,075,629 | $975.55k | Insider |
| Sphera Funds Management Ltd | 5.90% | 1,929,297 | $906.77k | Institution |
| Ally Bridge Group Ny LLC | 4.54% | 1,484,699 | $697.81k | Institution |
| Altium Capital Management LLC | 1.76% | 574,248 | $269.90k | Institution |
| Allostery Investments LP | 0.71% | 233,703 | $109.84k | Institution |
| Madge K. Shafmaster | 0.64% | 208,333 | $97.92k | Insider |
PMN vs Biotech Stocks
Promis Neurosciences Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.